Technology
Health
Pharmaceutical

Roche

$33.90
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.21%) Today
+$0.04 (0.12%) After Hours

Why Robinhood?

You can buy or sell Roche and other stocks, options, ETFs, and crypto commission-free!

About

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. Read More The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. RHHBY is listed on the OTCQX International Premier market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
94,442
Headquarters
Basel, Basel-Stadt (Basle Town)
Founded
1896
Market Cap
188.50B
Price-Earnings Ratio
21.46
Dividend Yield
2.22
Average Volume
1.34M
High Today
$33.90
Low Today
$33.72
Open Price
$33.81
Volume
367.73K
52 Week High
$34.98
52 Week Low
$26.30

Collections

Technology
Health
Pharmaceutical
Healthcare
Europe (Non-UK)
Europe

News

Yahoo FinanceMar 15

Roche Gets Approval for Label Expansion of MabThera in Europe

Roche Holdings AG RHHBY announced that the European Commission has approved a label expansion of its rheumatoid arthritis (RA) drug, MabThera.

75
Yahoo FinanceMar 15

Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity Pharmaceuticals Inc. INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity for use in MARIO-3, a phase II multi-arm combination cohort study. The study will evaluate Infinity’s lead immuno-oncology candidate, IPI-549in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and IPI-549 in combinat...

53
Yahoo FinanceMar 15

Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others

This week the FDA and European Commission were quite active. Pfizer PFE announced FDA approval for its biosimilar version of Roche’s RHHBY breast cancer medicine, Herceptin while Merck MRK and Roche gained approval in EU to expand labels of their marketed drugs, Keytruda and Hemlibra, respectively. Meanwhile, the FDA granted a 10-month review period to Allergan’s AGN regulatory application for key pipeline candidate ubrogepant while J&J JNJ filed an application with the same authority looking for approval o...

159
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.